Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 9/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29329606 | 0.90 | CYP4F2 (0.36) | CYP4F2CYP4A11GCKFFAR4RARG | |
| SCHEMBL21982871 | 0.86 | CYP4F2 (0.37) | CYP4F2CYP4A11GCKFFAR4MTNR1A | |
| SCHEMBL20325098 | 0.86 | CYP4F2 (0.37) | CYP4F2CYP4A11GCKFFAR4MTNR1A | |
| SCHEMBL26030360 | 0.86 | CYP4F2 (0.39) | CYP4F2CYP4A11GCKFFAR4RARG | |
| SCHEMBL20133413 | 0.86 | CYP4F2 (0.39) | CYP4F2CYP4A11GCKFFAR4RARG | |
| SCHEMBL22560664 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11GCKFFAR4MTNR1A | |
| SCHEMBL21472028 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11GCKFFAR4RARG | |
| SCHEMBL20443306 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11GCKFFAR4RARG | |
| SCHEMBL18592300 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11GCKFFAR4MTNR1A | |
| SCHEMBL18592294 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11GCKFFAR4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | CYP4F2 4592/4885CYP4A11 4006/4885GCK 2679/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP4F2 4592/4885CYP4A11 4006/4885GCK 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.